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Introduction
Childhood acute transverse myelitis (ATM), an inflammatory involvement 
of spinal cord, is a rare demyelinating and immune-mediated disorder of 
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Abstract
Objective
Acute transverse myelitis (ATM) is a rare inflammatory demyelinating 
disorder characterized by relatively acute onset of motor, sensory, and 
autonomic dysfunction. Children comprise 20% of total cases of ATM. In 
this review, we described the current literature on childhood ATM, focusing 
on the epidemiology, pathogenesis, clinical presentation, approach to 
diagnosis, differential diagnosis, treatment and outcome in the pediatric 
population. 
Materials &Methods
We searched the related articles in electronic databases such as Scopus, 
EMBASE, Google Scholar, and PubMed. All study designs were included 
and the essential key words for searching were myelitis, acute transverse 
myelitis, childhood transverse myelitis, and acquired demyelinating 
syndromes. 
Results
The related data focusing on the epidemiology, pathogenesis, clinical 
presentation, diagnostic approach and differential diagnosis, treatment and 
outcome of pediatric ATM were gathered and described. 
Conclusion
ATM is a heterogeneous disorder in children with a broad spectrum of 
clinical presentation, etiology, and outcome. It may be the first presentation 
of relapsing acquired demyelinating syndromes and also must be 
distinguished from compressive and noninflamatory myelopathies. Correct 
diagnosis is crucial for treatment and prognosis. 
Keywords: Acute transverse myelitis, Acquired demyelinating syndromes, 
Childhood transverse myelitis, Myelitis
8central nervous system (CNS) (1). It is potentially 
a devastating disorder with variable outcomes that 
characterized by relatively acute onset of motor, 
sensory, and autonomic dysfunction (2). ATM 
may be the harbinger presentation of relapsing 
acquired demyelinating syndromes (ADS) such 
as multiple sclerosis (MS), acute disseminated 
encephalomyelitis (ADEM), and neuromyelitis 
optica (NMO). It can occur, however, as an isolated 
condition, usually after an infectious disorder. It is 
important to distinguishing ATM from compressive 
and noninflammatory myelopathies. Diagnostic 
evaluation, prognosis, recurrence risk, and 
treatment plans are different among these entities.
In this review, we described the current literature 
on childhood ATM, focusing on the epidemiology, 
pathogenesis, clinical presentation, approach to 
diagnosis, differential diagnosis, treatment and 
outcome in the pediatric population. 
Materials &Methods
We searched the related articles in electronic 
databases such as Scopus, EMBASE, Google 
Scholar, and PubMed. All study designs were 
included and the essential key words for searching 
were myelitis, acute transverse myelitis, childhood 
transverse myelitis, acquired demyelinating 
syndromes. The related data focusing on the 
epidemiology, pathogenesis, clinical presentation, 
diagnostic approach and differential diagnosis, 
treatment and outcome of pediatric ATM were 
gathered and described.
Results
Epidemiology  
The incidence of pediatric ATM is 1.7-2 per 
million children yearly (3). Male to female ratio 
is 1.1–1.6:1 (1), but a female predominance is 
reported in teenager cases associated with MS or 
NMO (4–6). ATM occurs in adults more common. 
Children comprise 20% of total cases of ATM (7). 
ATM encompasses one-fifth of pediatric cases 
that present with a first ADS(8). Age distribution 
of pediatric ATM is bimodal primarily affected 
children under 5 and older than 10 yr of age (9,10) 
. There is no ethnic predisposition (1). A preceding 
infection or vaccination is reported in up to 66% 
and 28% of children with ATM respectively, during 
30 d before the onset of the disease (7,9,11) . Mild 
spinal trauma or allergic shot may be preceding 
risk factors (12).
Clinical features:
The first presentation of ATM in children is usually 
back pain. Rapidly progressive motor deficits 
develop in the lower extremities. Initially, flaccid 
paresis and decreased deep tendon reflexes (DTRs) 
are often detected, but subsequently, this condition 
evolves to a state of increased tone and increased 
DTRs below the level of lesion during subsequent 
days up to 12 wk (12). Upper extremities also 
may be involved in the spinal cord lesion is in the 
thoracic region (12). Sensory deficits such as pain, 
burning paresthesia, hyperesthesia and numbness 
and sphincter dysfunction are also present (9,13). 
Urinary retention resulting in catheterization is 
seen in the most of the children (7,9). Autonomic 
dysfunction is common including variations in 
body temperature and instability in respiratory 
rate as well as heart rate and rhythm; also, 
urinary symptoms such as urgency, incontinency, 
and difficulty in voiding have been reported. 
Patients can experience intestinal dysfunction as 
constipation or incontinency(12,14). Priapism and 
visual loss have also been reported (12). Urinary 
retention may be the first presentation of myelitis 
(15). It is seen in 95% of the patients during the 
acute phase and its reason is disruption of the signal 
between the micturition center in the pons and the 
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9sacral level (12). Sensory level is detectable in the 
majority of patients mostly in the thoracic region 
(12). The border of sensory level establishes the 
level of spinal cord involvement that is an essential 
factor in determining the prognosis of the disease 
(16). In up to 40% of children, a clear sensory 
level may not be assessed (9,10,17). Neurologic 
symptoms progress during next 2-4 d and reach a 
nadir within 5-6 d of onset (6,9,18). The length of 
the plateau phase of symptoms is 1 wk (range, 1-40 
d) (12).
Initial recovery occurs nearly 9 d after the onset of 
the disease (range, 2-50 d) (12). The first symptoms 
to resolve after starting treatment are pain and 
then motor deficits. Sensory deficits and urinary 
dysfunction may need longer time to resolve(9). 
The time to walking is the least predictable (ranges 
2 d- 1 yr) (12). 
Subtypes of ATM are described based on the clinical 
severity as well as the nature and extent of spinal 
cord involvement in imaging. Acute complete 
transverse myelitis (ACTM) includes symmetric 
motor, sensory and autonomic dysfunction on both 
sides below the level of the lesion concurrent with 
MRI lesions in one to two vertebral segments. In 
acute partial transverse myelitis (APTM), clinical 
presentation can be mild or asymmetric with 
involvement of one to two vertebral segments in 
MRI. Longitudinally extensive transverse myelitis 
(LETM) describes complete or incomplete 
dysfunction of the spinal cord with a lesion 
extending over three or more vertebrae (9,10,17). 
LETM occurs in 66%-85% of pediatric ATM (2,5) 
and could be associated with NMO and ADEM- 
associated TM (7). Otherwise, MS is frequently 
associated with segmental TM involving fewer 
than three vertebral segments (12). An enhancing 
signal abnormality can be usually seen over one 
or more vertebrae in spinal cord MRI (9). Absence 
of gadolinium-enhancing of the lesion does not 
rule out ATM (2,5,7). Essentially, the lesions are 
centrally located within gray matter and can be 
discrete or contagious (5). The most lesions are 
cervical (64%-76%) and cervicothoracic (5,7,18). 
Generally, brain MRI is normal in idiopathic ATM, 
although asymptomatic lesions are seen in more 
than 40% of the patients and predict a higher risk 
of developing NMO or MS (2). Therefore, brain 
MRI is necessary for the evaluating TM patients 
(10). MS often (66%-88%) occurs in children with 
APTM associated with cerebral lesion in MRI 
(10,17). 
Cerebrospinal fluid (CSF) findings are 
lymphocytosis (usually less than 100/mm3) 
and increased protein level (usually 100-120 
mg/dl). In 20%-50% of children with definite 
ATM, CSF analysis shows normal protein 
levels and white blood cells count (5,7,9,11). In 
isolated ATM, oligoclonal bands (OCBs) in CSF 
usually are not detected. However, OCBs are 
elevated in one-third of LETM patients (12). If 
OCBs are detected in CSF, an increased risk of 
subsequent MS is expected; subsequent MS is 
expected (19,20)”container-title”:”Archives of 
neurology”,”page”:”357-362”,”volume”:”69”,”is
sue”:”3”,”ISSN”:”0003-9942”,”journalAbbreviat
ion”:”Archives of neurology”,”author”:[{“family
”:”Bourre”,”given”:”Bertrand”},{“family”:”Zéph
ir”,”given”:”Hélène”},{“family”:”Ongagna”,”giv
en”:”Jean-Claude”},{“family”:”Cordonnier”,”giv
en”:”Charlotte”},{“family”:”Collongues”,”given
”:”Nicolas”},{“family”:”Debette”,”given”:”Step
hanie”},{“family”:”Fleury”,”given”:”Marie-Celi
ne”},{“family”:”Outteryck”,”given”:”Olivier”},{
“family”:”Hannequin”,”given”:”Didier”},{“famil
y”:”Vermersch”,”given”:”Patrick”}],”issued”:{“d-
ate-parts”:[[“2012”]]}},”label”:”page”},{“id”:40
,”uris”:[“http://zotero.org/users/local/0XmY0cgj/
i tems/33WP2UIB”],”uri”: [“ht tp: / /zotero.
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org/users/local/0XmY0cgj/i tems/33WP2U
IB”],”itemData”:{“id”:40,”type”:”article-
journal”,”title”:”Importance of paraclinical and 
CSF studies in the diagnosis of MS in patients 
presenting with partial cervical transverse 
myelopathy and negative cranial MRI”,”container-
title”:”Multiple Sclerosis Journal”,”page”:”312-
316”,”volume”:”6”,”issue”:”5”,”ISSN”:”1352-
4585”,”journalAbbreviation”:”Multiple Sclerosis 
Journal”,”author”:[{“family”:”Bashir”,”given”:
”K”},{“family”:”Whitaker”,”given”:”JN”}],”is
sued”:{“date-parts”:[[“2000”]]}},”label”:”page
”}],”schema”:”https://github.com/citation-style-
language/schema/raw/master/csl-citation.json”} .
The most cases of ATM develop as an isolated post 
infectious disease (idiopathic ATM), but ATM can 
occur associated with other neuroinflammatory 
disorders including NMO, MS, and ADEM 
(secondary or disease-associated ATM). ATM 
can be associated with some other CNS disorders 
consisting of infections due to some pathogens 
such as Cytomegalovirus, Herpes viruses, 
Enteroviruses, Epstein-Barr virus, influenza virus, 
hepatitis A,B and C viruses, West Nile virus, 
HTLV1, mycoplasma, Varicella-Zoster virus (21), 
Zica virus (22), tuberculosis, neurosarcoidosis; 
and paraneoplastic syndromes. A few systemic 
inflammatory diseases also can be associated with 
ATM including systemic lupus erythematosus 
(SLE), mixed connective tissue disease (MCTD), 
primary Antiphospholipid antibody syndrome, 
Sjogren syndrome (SS) and Behcet disease (23–25).
Pathogenesis
Histologic findings are different in idiopathic and 
disease-associated ATM, but inflammation and 
neural loss are seen in both (26). Monocyte and 
lymphocyte infiltrations in the lesion and axonal 
degeneration are reported and both gray and 
white matters are involved (27). In fact, ATM is 
a combined inflammatory disease that involves 
multiple components of CNS including neurons, 
axons, oligodendrocytes, and myelin rather than a 
pure demyelinating disease (26). Histopathologic 
studies in adults show intralesional infiltration of 
monocytes and CD4+ and CD8+ T lymphocytes 
associated with astrocyte and microglia activation 
(28). Necrosis and cavitation may occur 
especially in NMO, resulting in severe disability 
(29). There have been described two potential 
mechanisms of autoimmunity in ATM including 
molecular mimicry and superantigen effect (26). 
A pediatric study showed significant increase 
in the Interleukin-6 (IL-6) levels in the CSF of 
the children with ATM (30). IL-6 plays role in 
cellular injury of the spinal cord. An association 
between increased IL-6 levels and disability has 
been shown (31). Studies showed a decreased IL-6 
response to monoclonal antibody trial in early 
phase of ATM with appropriate outcome in NMO 
and ATM patients (32). Various autoantibodies 
are implicated in ADS by crossing the blood-
brain barrier such as aquaporin-4 and myelin 
oligodendrocyte glycoprotein (MOG) antibodies 
in NMO and childhood ADS, respectively. The 
latter may be predicted a non-MS course (33). 
Some autoantibodies also may directly damage 
neurons that expose antigens which cross-react 
with antibodies against infectious organisms (34).
Diagnosis and evaluation
The diagnosis of TM is proposed when the patient 
present with signs and symptoms of bilateral 
sensory, motor and autonomic dysfunction 
localized to one or more spinal segments without 
evidence of a cord compression. Therefore, the 
following criteria are necessary for the diagnosis 
of ATM:
1- Exclusion of compressive lesions, and
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2- Confirmation of spinal cord inflammation as 
detected by the following:
2-1) the gadolinium enhancing lesion in MRI, or 
2-2) CSF evidence of either pleocytosis or elevated 
immunoglobulin type G (IgG) index
However, the lack of the inflammation markers 
does not exclude ATM (23). Developing symptoms 
of myelopathy considered as an emergency 
condition since severe squealed can occur if the 
disorder is not diagnosed and treated promptly 
(1). Emergent spinal MRI is required to exclude 
a compressive lesion. After that, determination of 
inflammatory or noninflammatory myelopathy is 
necessary according to above-mentioned markers. 
If inflammation is present and TM is suspected, 
then some investigations are recommended (35). 
Brain MRI with and without contrast for detecting 
MS or ADEM; CSF analysis for cell count, 
protein, glucose, OCBs, IgG index, and cytology; 
serum NMO IgG antibodies (anti-aquaporin-4 
IgG); serum B12; methylmalonic acid; human 
immunodeficiency antibodies; thyroid function 
test; antiphospholipid antibodies, antinuclear 
antibodies, rheumatoid factor and anti-dsDNA 
(35). In more than 40% of children, asymptomatic 
brain MRI lesions are seen and may be a risk factor 
for developing MS or NMO (2). Ophthalmologic 
consultation for detecting comorbid optic neuritis 
is recommended for all patients (12). Some 
children with encephalopathy and young children 
may not have complaints of vision impairments 
(12). Additionally, neurophysiological findings of 
subclinical optic neuritis may exist (12). 
Differential diagnosis
Three categories in the differential diagnosis of 
idiopathic ATM are as follows: 
1. Other forms of myelopathy such as compressive 
or noninflammatory including epidural hematoma, 
intervertebral disk herniation, vertebral body 
fracture, ischemic myelopathy due to arterial 
compromise or venous hypertension (36). Spinal 
cord tumors occasionally present with subacute 
pain and myelopathic symptoms. Extramedullary 
tumors consist of nerve sheet tumors, meningioma, 
and metastasis of medulloblastoma. Intramedullary 
tumors include astrocytoma and ependymoma (1). 
Spine tuberculosis is another cause of compressive 
myelopathy. Other noninflammatory causes are 
vitamins deficiency including B12, D, and E along 
with copper deficiency (35).
2. Secondary ATM including cases due to 
identified causes such as infectious myelitis, 
a rheumatological disease (e.g. SLE and SS), 
paraneoplastic syndromes, demyelinating CNS 
disease (e.g. ADEM, MS, and NMO). Enteroviruses 
have recently been reported to be mediated in acute 
flaccid myelitis due to direct invasion to motor 
neurons of spinal cord (37). Clear diagnosis of 
disease-associated TM by clinical and paraclinical 
features is important since the prognosis, treatment 
and recurrence risks are different (1). Patients with 
NMO typically have LETM (38).
3. Non myelopathic disorders can mimic ATM 
essentially Guillain-Barre syndrome (GBS). 
Clinical features of GBS including acute weakness 
and progressive motor and sensory dysfunctions 
resemble to ATM (39). However, some clinical 
and paraclinical factors help to discriminate them. 
Autonomic involvement in ATM present with 
intestinal or urinary urgency or retention, rather 
patients with GBS have cardiovascular instability. 
Sensory level is characteristic in ATM, while is 
never detected in GBS. IgG index in CSF and 
distinct spinal cord lesion in MRI are two findings 
in ATM but not detected in GBS patients. Finally, 
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in GBS, conduction block or delayed conduction of 
peripheral nerves may be seen in electro diagnostic 
studies, but these studies are usually normal in 
ATM patients (1). 
Regarding the onset time of the symptoms of spinal 
cord syndrome, differential diagnosis are classified 
as follows: symptoms with acute or hyperacute 
onset should prompt consideration of spinal 
infarct, hemorrhage or disk herniation. Slowly 
progressive onset of the symptoms is in the favor of 
compressive myelopathy such as tumor, nutritional 
deficits, toxin exposure and hereditary disorders 
such as hereditary spastic paraplegia. Subacute 
presentation is in the favor of demyelination (TM 
or NMO), infections, and vasculitis (SLE)
Treatment
US Food and Drug Administration approved 
no treatments for ATM since lack of controlled 
clinical trials (1). Therapies are according to the 
data from open-label and retrospective studies. 
In specific conditions, certain medications 
have better therapeutic results (40), such as 
cyclophosphamide therapy in SLE patients with 
ATM and plasmapheresis (PLEX) in patients with 
NMO. Standard first-line therapy in idiopathic 
ATM is intravenous high dose corticosteroids 
that are prescribed as 30 mg/kg/d (maximum 1 
gr/d) of methylprednisolone for 3-7 d (1,12,41). 
Outcome of the patients with mimics of ATM 
does not worsen by corticosteroids. Thus, the 
benefit of starting earlier therapy is preferable 
(1). The patients treated with corticosteroids have 
better short and long-term outcome (41,42) and 
the time of disability is shorter (43). Intravenous 
methylprednisolone should be followed by an 
oral steroid starting at 1 mg/kg/d and tapering 
over 3-4 wk (12,44). Plasmapheresis should be 
considered if clinical response does not begin or 
symptoms worsen during 24-48 h after starting 
steroids (12). Some centers use PLEX concurrent 
with steroids when significant motor or respiratory 
dysfunctions are present (45,46). Waiting until 
completing steroids therapy is not necessary for 
patients with serious deficits. Though, according 
to American Academy of Neurology guidelines 
published in 2011, benefits of PLEX is recognized 
in adult ATM patients (12). The preferred protocol 
is 5-7 treatments, each exchanging 1.1-1.5 plasma 
volumes and every other day for 10 d (47). 
Intravenous immunoglobulin 2 gr/kg divided over 
2-5 d is often used in fulminant cases, though 
limited evidence exist for its benefits (12,17). 
Cyclophosphamide 500-750 mg/m2 have been 
used in patients with SLE for improved outcome 
(12). Chronic immunomodulatory treatment by 
drugs such as azathioprine, methotrexate, or 
mycophenolate should be considered in patients 
with recurrent disease (34). 
In patients with the diagnosis of MS or NMO 
also, typical immunomodulatory drugs should 
be initiated after treatment of acute period 
(48). Consultation with physical medicine and 
rehabilitation specialists is necessary for beginning 
rehabilitation soon as soon possible (12). Bladder 
& Bowel continence programs should be initiated. 
In this regard, anticholinergic drugs such as 
oxybutynin or tolterodine may be helpful. In some 
patients, drugs such as gabapentin, carbamazepine, 
phenytoin, amitriptyline or baclofen may be needed 
to relieve pain (12). 
Prognosis and outcome
Outcome of ATM in children is better than adults, 
as almost 50% of children obtain recovery after 2 
yr (7,49). In general, outcomes are very different 
from complete recovery without sequelae to 
entire paralysis and even death (12). 33%-50% 
of the patients show complete recovery and 10%-
20% of cases have poor outcome (12,50). Infants 
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have the worst outcome (43). More frequency of 
LETM in infants and inability of immature brain to 
recover from injury in them are two reasons (12). 
Recovery phase can continue up to several years 
(12,51). Death is usually due to a high cervical 
cord injury and respiratory insufficiency (7,41). 
Sensory deficits and urinary dysfunction are the 
most common sequelae (15%-50%) (2). Nearly 
10%-20% of patients never obtain mobility or 
urinary function (1). Poorer outcomes have been 
associated with: younger age at the onset of the 
disease, rapid onset of symptoms, shorter time 
(less than 24 h) to maximal deficit, complete 
paraplegia, need to assisted ventilation, longer 
time to treatment, absence of CSF pleocytosis, 
higher border of sensory level, T1 hypointensities 
in spinal cord MRI and longitudinal extent of 
the cord lesions (1,23,42,52). Prognosis is better 
in TM associated with ADEM (12). TM in most 
patients is monophasic, but 25%-33% of the 
patients with idiopathic TM and as high as 70% 
of patients with disease-associated TM develop 
recurrences (50). Factors that predict recurrence 
include: longitudinally extensive lesions in 
spinal cord, brain lesions on MRI, existence of 
one or more autoantibodies (ANA, ds DNA, 
phospholipid antibody, C-ANCA), underlying 
collagen vascular disease, OCBs in CSF, presence 
of NMO-IgG (anti-Aquaporin-4)antibody (27,50) 
and female sex (1). Patients with LETM have an 
increased risk for NMO.LETM, recurrent ATM, 
ATM with concurrent or rapidly sequential optic 
neuritis suggest NMO (12). In addition, OCBs 
can be detected in 30% of patients with NMO 
(12). Besides, patients with OCBs in CSF have an 
increased risk for evolving MS (12). According to 
a Canadian study, MS develops in 13% of children 
with ATM (8). In addition, patients with patchy 
lesions involving 1-3 segments in cord, partial 
myelitis, and brain lesions in MRI have a rate of 
60%-90% progression to MS during 3-5 yr (53). A 
study has reported cognitive impairment in 10% of 
pediatric ATM patients. 
We suggested monitoring of this population 
for cognitive problems (54). Apart from initial 
outcome, ATM patients should be monitored 
longitudinally, either to clearing diagnosis or to 
provide rehabilitative interventions for motor 
deficits, urinary dysfunction, psychological and 
cognitive impairment (1).
In Conclusion, ATM is a heterogeneous disorder 
in children with a broad spectrum of clinical 
presentation, etiology, and outcome. It may be the first 
presentation of relapsing acquired demyelinating 
syndromes or occur as an isolated postinfectious 
condition. It also must be distinguished from 
compressive and noninflammatory myelopathies. 
Diagnostic evaluation, prognosis, recurrence risk, 
and treatment plans are different among these 
entities. Therefore, the correct diagnosis is crucial 
for treatment and prognosis.
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